Next-Generation Sequencer Enhances Genetic Research at UT Arlington

The North Texas Genome Center (NTGC) at UT Arlington is getting an upgrade in the form of a next-generation genetic sequencer that will allow researchers to study genetic links between health and disease at a large scale. The new $1 million instrument, the only one of its kind in North Texas, will allow faculty and students to more deeply analyze rare genetic variants, an important step in discovering new insights for the future of health care.

I'm excited to be able to expand and upgrade the technological capabilities of the North Texas Genome Center, a collaborative venture between UTA and other universities, medical centers and corporate partners. The NTGC was a leader during the early days of the COVID-19 outbreak. This new equipment will allow our scientists to further advance their research in genomics at reduced cost, compared to the past."

Kate C. Miller, vice president for research and innovation at UT Arlington

Called next-generation sequencing, this new technology will allow for additional DNA sequencing to discover new variants and better understand genome regulation.

"This addition to the NTGC will be a great asset for UTA's science researchers, particularly our faculty and students who have active genome research on many topics ranging from cancer biology and antibiotic-resistant tuberculosis to diseases killing coral reefs and snake bite treatments," said Morteza G. Khaledi, dean of the College of Science.

The upgrade to the University's core genome lab facility is especially welcome now, as UTA's is undertaking a faculty recruiting initiative, RISE 100, to hire 100 tenure-track faculty, 20 to 25 non-tenure-track research faculty and 40 postdoctoral researchers. The new faculty will amplify the impact of research at UTA as well as improve the undergraduate experience and enhance graduate education.

"This technology will be another asset for our top bioengineering faculty and students," said Peter Crouch, dean of the College of Engineering. "Some of the ongoing research we have now aims to understand damaging brain swelling in newborns and improve imaging tools to track problematic heart cells. The addition of this new genetic sequencer will be a great resource for investigators."

Founded in 2018, the NTGC is dedicated to using technology to help researchers better understand how genetic variations can lead to faster disease diagnoses, improved treatment outcomes and, ultimately, lower costs for health providers and patients.

"UTA's College of Nursing and Health Innovation's research integrates expertise of CONHI faculty with disciplinary expertise in nursing, kinesiology, public health, engineering and informatics, often incorporating interdisciplinary collaborations with other departments at UTA and researchers at other universities," said Elizabeth Merwin, dean of CONHI.

"Our extensive research ranges from basic sciences to clinical care to population health across the continuum of health and the health condition, with contributions spanning bone and muscle health, cardiovascular disease, health disparities, patient outcomes, exercise science and other health related areas," Dr. Merwin added. "The new gene sequencer will advance clinical translational sciences research, facilitate the integration of precision medicine into more research studies and enhance interdisciplinary research."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
How CRISPRi is Helping Combat Drug-Resistant Tuberculosis